STOCK TITAN

Bio-Techne Corporation - $TECH STOCK NEWS

Welcome to our dedicated page for Bio-Techne Corporation news (Ticker: $TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne Corporation stock.

Bio-Techne Corporation (NASDAQ: TECH) is a pioneering global life sciences company based in Minnesota. Specializing in bioactive tools and reagents, Bio-Techne serves the research and clinical diagnostic communities. The company's extensive product portfolio, exceeding 275,000 items, supports scientific investigations into biological processes and disease mechanisms, facilitating both drug discovery and accurate clinical testing.

Bio-Techne operates through two main segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment, which accounts for 75% of revenue, provides reagents such as antibodies and analytical instruments for life sciences research. The Diagnostics and Genomics segment, representing 25% of revenue, offers diagnostic reagents and molecular diagnostics, with a strong footprint in spatial biology products.

Geographically, the United States is Bio-Techne's largest market, contributing about 55% of its revenue. The company also maintains significant operations in Europe, the Middle East, Africa (20%), the UK (5%), and Asia-Pacific (15%).

In recent news, Bio-Techne has been active on multiple fronts:

  • Legal Actions: Bio-Techne initiated legal proceedings in the Unified Patent Court to address patent infringements related to its RNAscope® ISH technology by Molecular Instruments, Inc.
  • Innovations: Partnering with Novomol-Dx, Bio-Techne introduced the Bio-Marker Pathfinder (BMP), a point-of-care ocular biomarker kit leveraging its Ella™ platform for rapid diagnostics in ophthalmic diseases.
  • Strategic Collaborations: Bio-Techne entered a distribution agreement with Thermo Fisher Scientific to expand product access across Europe and announced continued collaboration with Regulus Therapeutics, highlighting positive results in ADPKD treatment using Bio-Techne's Simple Western™ platforms.
  • Financial Performance: Bio-Techne reported a modest 3% revenue increase for Q3 FY2024 despite challenging market conditions, underscoring strong operational execution and strategic investments.
  • Product Showcases: The company unveiled its MauriceFlex™ System at the 72nd ASMS Conference, demonstrating innovative solutions for protein characterization.

With over 3,100 employees worldwide, Bio-Techne generated over $1.1 billion in net sales in fiscal 2023. The company continues to drive significant advancements in life sciences and healthcare through its robust portfolio and strategic initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
partnership
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
covid-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
dividends
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
covid-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
none

FAQ

What does Bio-Techne Corporation do?

Bio-Techne Corporation provides innovative bioactive tools and reagents that support scientific investigations, drug discovery, and clinical diagnostics.

What are Bio-Techne's main business segments?

Bio-Techne operates through two main segments: Protein Sciences and Diagnostics and Genomics.

Where is Bio-Techne headquartered?

Bio-Techne is headquartered in Minnesota, USA.

Which markets does Bio-Techne serve?

Bio-Techne serves the pharma, biotech, academic, and diagnostic markets globally, with significant operations in the USA, Europe, Asia-Pacific, and other regions.

What recent legal actions has Bio-Techne taken?

Bio-Techne has taken legal action against Molecular Instruments, Inc. in the Unified Patent Court to address patent infringements related to its RNAscope® ISH technology.

What is the Bio-Marker Pathfinder (BMP) kit?

Co-developed with Novomol-Dx, the BMP kit is an ocular biomarker kit running on Bio-Techne's Ella™ platform, designed for rapid diagnostics in ophthalmic diseases.

What was Bio-Techne's financial performance in Q3 FY2024?

Bio-Techne reported a 3% revenue increase for Q3 FY2024, highlighting strong operational execution despite challenging market conditions.

What is the MauriceFlex™ System?

The MauriceFlex™ System is an imaged capillary isoelectric focusing (icIEF) solution for protein characterization, recently showcased at the ASMS Conference.

How many employees does Bio-Techne have?

Bio-Techne has approximately 3,100 employees worldwide.

What was Bio-Techne's revenue in fiscal 2023?

Bio-Techne generated over $1.1 billion in net sales in fiscal 2023.

Bio-Techne Corporation

Nasdaq:TECH

TECH Rankings

TECH Stock Data

12.20B
155.39M
0.97%
100.54%
3.39%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
MINNEAPOLIS

About TECH

bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide.